| Literature DB >> 20946620 |
Mais Ammari1, Fiona M McCarthy, Bindu Nanduri, Lesya M Pinchuk.
Abstract
BACKGROUND: Bovine Viral Diarrhea Virus (BVDV) infection is widespread in cattle worldwide, causing important economic losses. Pathogenesis of the disease caused by BVDV is complex, as each BVDV strain has two biotypes: non-cytopathic (ncp) and cytopathic (cp). BVDV can cause a persistent latent infection and immune suppression if animals are infected with an ncp biotype during early gestation, followed by a subsequent infection of the cp biotype. The molecular mechanisms that underscore the complex disease etiology leading to immune suppression in cattle caused by BVDV are not well understood.Entities:
Mesh:
Year: 2010 PMID: 20946620 PMCID: PMC3026383 DOI: 10.1186/1471-2105-11-S6-S9
Source DB: PubMed Journal: BMC Bioinformatics ISSN: 1471-2105 Impact factor: 3.169
Figure 1Identification and analysis of protein profiles of bovine monocytes infected with cp and ncp BVDV biotypes. Process flowchart showing the major steps in bovine monocytes infection, protein isolation, identification and analysis with corresponding figures and tables.
Figure 2Distribution of total proteins identified in BVDV-infected monocytes compared to uninfected controls Using 2D-LC ESI MS/MS approach a total of 2489, 2356 and 2028 bovine proteins were identified in uninfected, ncp and cp BVDV infected bovine monocytes within two replicates respectively. Distribution of identified proteins compared to uninfected monocytes is shown for (A) ncp infection; and (B) cp infection.
Figure 3Differentially expressed host proteins in BVDV-infected monocytes compared to uninfected controls Compared to uninfected monocytes, ncp infection differentially alters the expression of 137 host proteins with 40.2% down-regulated proteins and 59.8% up-regulated proteins. Whereas, compared to uninfected monocytes, cp infection alters the expression of 228 host proteins with increasing the percentage of down-regulated proteins to 72% and decreasing the percentage of up-regulated proteins to 28% compared to the effect of ncp on uninfected monocytes.
Figure 4GO annotation for differentially expressed proteins in BVDV-infected monocytes The numbers of GO annotated bovine proteins are shown as a percentage. Since only 22-29% initially had GO annotation available, we added our own additional GO annotations. In total we obtained GO annotation for 91.2% and 91.7% of our differentially altered host response proteins due to ncp and cp BVDV-infection, respectively.
Figure 5GO functional analysis of host proteins differentially expressed during ncp or cp BVDV-infected monocytes The cp and ncp host proteins that were differentially expressed compared to uninfected monocytes were functionally analyzed by summarizing GO functional annotations based on the GOA and Whole Proteome GOSlim set and the results were compared to obtain the relative differences between the two biotypes. The top under- and over- represented GO functions are shown here: A. Molecular Functions (MF), B. Biological Process (BP) and C. Cellular Components (CC). Subcategories within functional groups are listed on the y-axis and the relative percentage difference in the numbers of proteins altered by cp and ncp is the x-axis.
Top ten functions/diseases and their respective top ten pathways in ncp BVDV- infected monocytes
| Acute phase response signaling (8) | Caveolae- mediated endocytosis signaling (5) | B cell development (3) | IL-10 signaling(3) | Macropinocytosis signaling (3) | Virus entry via endocytic pathway (3) | Antigen presentation pathway (2) | Fcy receptor mediated phagocytosis in macrophages and monocytes (3) | Integrin signaling (4) | Primary immunodeficiency signaling (2) | |
|---|---|---|---|---|---|---|---|---|---|---|
| ITGB3 | SPN | – | CSF1R, ITGB3 | ITGB3 | – | FGR | ITGB3 | – | ||
| – | ITGA6, ITGB3 | SPN, PTPRC | CD14 | CSF1R, ITGB3, CD14 | ITGA6, ITGB3 | – | FGR | ITGA6, ITGB3 | PTPRC | |
| TF | ITGA6, ITGB3 | SPN, PTPRC | CD14 | CSF1R, ITGB3, CD14 | ITGA6, ITGB3 | – | FGR | ITGA6, ITGB3 | PTPRC | |
| SOD2 | – | PTPRC, HLA- DRB1 | CD14 | CSF1R, ITGB3 | – | HLA-DRB1 | FGR | PTPRC | ||
| TF | ITGA6, ITGB3 | SPN, PTPRC, HLA-DRB1 | CD14 | CSF1R, ITGB3, CD14 | ITGA6, ITGB3 | – | FGR | ITGA6, ITGB3 | PTPRC | |
| – | ITGB3 | PTPRC | CD14 | CSF1R, ITGB3, CD14 | ITGB3 | – | FGR | ITGB3 | PTPRC | |
| – | ITGB3 | – | – | ITGB3 | ITGB3 | – | FGR | ITGB3 | – | |
| – | – | PTPRC | CD14 | CD14 | – | – | – | – | PTPRC | |
| A2M | – | PTPRC | CD14 | CSF1R, CD14 | – | – | FGR | – | – | |
| – | ITGB3 | PTPRC | – | ITGB3 | ITGB3 | – | – | ITGB3 | PTPRC |
TF: Transferrin; SOD2: Superoxide Dismutase 2, mitochondrial; A2M: Alpha-2-Macroglobulin; ITGB6: Integrin, Beta 6; ITGB3: Integrin, Beta 3 (platelet glycoprotein IIIa, antigen CD61); SPN: Sialophorin; PTPRC: Protein Tyrosine Phosphatase, Receptor type, C; CSF1R: Colony Stimulating Factor 1 Receptor; FGR: Fibrinogen Gamma Chain Numbers between brackets indicates the number of altered proteins involved in the functions/diseases or pathway
Top ten functions/diseases and their respective top ten pathways in cp BVDV- infected monocytes
| Acute phase response signaling(12) | Fcy receptor mediated phagocytosis in macrophages and monocytes (8) | Actin cytoskeleton signaling (8) | Antigen presentation pathway (3) | B cell development (3) | RhoA signaling(5) | Caveolae- mediated endocytosis signaling (4) | Clathrin- mediated endocytosis signaling (6) | IL-10 signaling(3) | Interferon signaling(2) | |
|---|---|---|---|---|---|---|---|---|---|---|
| – | FGR, LYN | – | – | – | – | ITGB3 | ITGB3 | – | – | |
| F2 | FGR, LYN | CD14, F2 | – | – | – | ITGB3 | F2, ITGB3 | CD14 | – | |
| F2 | FGR, LYN | CD14, F2 | TAPBP | HLA-DQB1 | – | ITGB3 | F2, ITGB3 | CD14 | – | |
| – | FGR, LYN | – | – | – | – | – | – | – | – | |
| – | FGR, LYN | – | – | – | – | – | – | – | – | |
| – | FGR, LYN | – | – | – | – | ITGB3 | ITGB3 | – | – | |
| – | FGR, LYN | – | – | – | – | – | – | – | – | |
| – | FGR, LYN | – | – | – | – | ITGB3 | ITGB3 | – | – | |
| F2 | FGR, LYN | CD14, F2 | – | SPN | – | ITGB3 | F2, ITGB3 | CD14 | – | |
| F2 | FGR, LYN | F2 | – | SPN | – | ITGB3 | F2, ITGB3 | – | – | |
F2: Coagulation Factor II (thrombin); FGR: Fibrinogen Gamma Chain; LYN: v-yes-1 Yamaguchi sarcoma viral related oncogene homolog; TAPBP: TAP Binding protein (Tapasin); SPN: Sialophorin; ITGB3: Integrin, Beta 3 (platelet glycoprotein IIIa, antigen CD61) Numbers between brackets indicates the number of altered proteins involved in the functions/diseases or pathway
Differentially altered proteins represented in top ten immunological pathways when comparing cp to ncp BVDV infection
| Regulation | ||||
|---|---|---|---|---|
| Symbol | Entrez Gene Name | Cp | Ncp | Pathways |
| heme oxygenase (decycling) 1 | Up | Up | Acute Phase Response Signaling, Fcy Receptor-mediated Phagocytosis in | |
| Macrophages and Monocytes, IL-10 Signaling | ||||
| albumin | Down | Down | Acute Phase Response Signaling, Caveolar-mediated Endocytosis Signaling | |
| haptoglobin | Down | Down | Acute Phase Response Signaling | |
| superoxide dismutase 2, mitochondrial | Up | Up | Acute Phase Response Signaling | |
| transferrin | Up | Up | Acute Phase Response Signaling, Clathrin-mediated Endocytosis Signaling | |
| apolipoprotein H (beta-2-glycoprotein I) | Up | – | Acute Phase Response Signaling | |
| apolipoprotein A-I | Up | – | Acute Phase Response Signaling | |
| alpha-2-HS-glycoprotein | Up | Up | Acute Phase Response Signaling | |
| serpin peptidase inhibitor, clade A (alpha-1 | Up | Up | Acute Phase Response Signaling | |
| antiproteinase, antitrypsin), member 1 | ||||
| alpha-2-macroglobulin | Up | Up | Acute Phase Response Signaling | |
| fibrinogen gamma chain | Up | – | Acute Phase Response Signaling | |
| coagulation factor II (thrombin) | Up | Acute Phase Response Signaling, Actin Cytoskeleton Signaling, Clathrin- | ||
| mediated Endocytosis Signaling | ||||
| ARP3 actin-related protein 3 homolog (yeast) | Up | Up | Fcy Receptor-mediated Phagocytosis in Macrophages and Monocytes, Actin | |
| Cytoskeleton Signaling, RhoA Signaling, Clathrin-mediated Endocytosis | ||||
| Signaling | ||||
| actin related protein 2/3 complex, subunit 2, | Up | Fcy Receptor-mediated Phagocytosis in Macrophages and Monocytes, Actin | ||
| 34kDa | Cytoskeleton Signaling, RhoA Signaling, Clathrin-mediated Endocytosis | |||
| Signaling | ||||
| ezrin | Down | Fcy Receptor-mediated Phagocytosis in Macrophages and Monocytes, Actin | ||
| Cytoskeleton Signaling, RhoA Signaling | ||||
| v-yes-1 Yamaguchi sarcoma viral related | Up | Fcy Receptor-mediated Phagocytosis in Macrophages and Monocytes | ||
| oncogene homolog | ||||
| talin 1 | Down | – | Fcy Receptor-mediated Phagocytosis in Macrophages and Monocytes | |
| FYN binding protein (FYB-120/130) | Down | – | Fcy Receptor-mediated Phagocytosis in Macrophages and Monocytes | |
| Gardner-Rasheed feline sarcoma viral (v-fgr) | Down | Down | Fcy Receptor-mediated Phagocytosis in Macrophages and Monocytes | |
| oncogene homolog | ||||
| myosin, heavy chain 10, non-muscle | Up | – | Actin Cytoskeleton Signaling | |
| myosin, light chain 6, alkali, smooth muscle and | Up | Actin Cytoskeleton Signaling, RhoA Signaling | ||
| non-muscle | ||||
| diaphanous homolog 3 (Drosophila) | Down | – | Actin Cytoskeleton Signaling | |
| CD14 molecule | Up | Up | Actin Cytoskeleton Signaling, IL-10 Signaling | |
| IQ motif containing GTPase activating protein 1 | _ | Up | Actin Cytoskeleton Signaling | |
| major histocompatibility complex, class II, DR | Up | Up | Antigen Presentation Pathway, B Cell Development | |
| beta 1 | ||||
| transporter 1, ATP-binding cassette, sub-family | Down | Down | Antigen Presentation Pathway, Interferon Signaling | |
| B (MDR/TAP) | ||||
| TAP binding protein (tapasin) | Down | – | Antigen Presentation Pathway | |
| major histocompatibility complex, class II, DQ | Down | B Cell Development | ||
| beta 1 | ||||
| sialophorin | Down | Down | B Cell Development | |
| protein tyrosine phosphatase, receptor type, C | _ | Up | B Cell Development | |
| kinectin 1 (kinesin receptor) | Down | Down | RhoA Signaling | |
| integrin, alpha 2b (platelet glycoprotein IIb of | Up | Down | Caveolae-mediated Endocytosis Signaling | |
| IIb/IIIa complex, antigen CD41) | ||||
| filamin A, alpha | Up | Up | Caveolae-mediated Endocytosis Signaling | |
| integrin, beta 3 (platelet glycoprotein IIIa, | Up | Down | Caveolae-mediated Endocytosis Signaling, Clathrin-mediated Endocytosis | |
| antigen CD61) | Signaling | |||
| integrin, alpha 6 | – | Down | Caveolae-mediated Endocytosis Signaling | |
| SH3-domain GRB2-like endophilin B1 | Down | – | Clathrin-mediated Endocytosis Signaling | |
| arginase, type II | Up | Up | IL-10 Signaling | |
| myxovirus (influenza virus) resistance 1, | Up | Interferon Signaling | ||
| interferon-inducible protein p78 (mouse) | ||||